Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

MedPage Today) — SAN FRANCISCO — Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline Depot) to everolimus (Afinitor…